Divi's Labs (DIVISLAB) Q1 FY27 Concall: PAT Margin 28.7%, Capex Near Done

Divi's Laboratories (DIVISLAB) - Share price: ₹11,180 (screener.in, 21 November 2026) - Market cap: ₹2,96,807 crore - P/E: 86.9 (Laurus Labs 92.5, Sun Pharma 36.8, Dr Reddy's 41.5 on screener.in) - ROCE: 22.0%

Divi's Laboratories (DIVISLAB) posted Q1 FY27 profit after tax of ₹902 crore, up 65%, as custom synthesis grew to 60% of sales.

Divi's Labs Q1 FY27 results: what the concall said

Divi's Laboratories was incorporated in 1990. It makes active ingredients for medicines (APIs), custom-made molecules for drug companies (custom synthesis, or CDMO) and nutraceutical ingredients. It is listed on NSE as DIVISLAB and on BSE (532488). About 90% of standalone revenue is exports, and Europe and North America take 75% of those exports.

This article uses the Q1 FY27 earnings call held on 1 August 2026 (transcript filed on 6 August 2026). The June 2026 quarter numbers, as management read them out:

₹ crore Q1 FY26 Q1 FY27 Change ------------ Consolidated total income 2,529 3,144 +24% Consolidated profit before tax 733 1,180 +61% Consolidated profit after tax 545 902 +65% Standalone total income 2,476 3,037 +23% Standalone profit before tax 747 1,165 +56% Standalone profit after tax 557 891 +60%

Standalone revenue grew 10% in constant currency. Profit grew much faster than sales, so the profit after tax margin on total income went from about 21.5% to about 28.7% (₹545 crore on ₹2,529 crore, and ₹902 crore on ₹3,144 crore).

Why Divi's Labs margins are expanding: custom synthesis mix

Custom synthesis made 60% of standalone revenue in Q1 FY27 and generics 40%. Management says custom synthesis work is lumpy, so it asks investors to judge margins over a year, not one quarter. Net material consumption was 31.2% of standalone revenue from operations. Management links this to making key starting materials and intermediates in-house.

- Nutraceuticals brought in ₹298 crore, against ₹250 crore a year earlier. The segment is 20 years old and now has over 100 products. - The net forex loss was ₹7 crore, against a gain of ₹39 crore a year earlier. - Solvent costs stayed high for much of the quarter. Management said some solvents cost two to three times more than before because of the West Asia conflict, and it is talking to customers about sharing the cost. - The company holds about three months of raw material stock, bought at higher prices, to avoid any production stoppage. Inventory was ₹4,413 crore at 30 June 2026.

Divi's Labs capex and capacity expansion

Three large capex projects are close to done. Management said they are about 70% complete, and that about 70% of the roughly ₹2,000 crore announced earlier has been capitalised. The company capitalised ₹451 crore in the quarter. Capital work in progress was ₹2,034 crore at 30 June 2026.

- Validation batches for the three projects have been completed. Commercial supply starts only after the customers and the drug regulators approve. Management said it cannot share quantities or order values because of confidentiality agreements. - Utilisation is about 85% across the three units. - The Kakinada unit (Unit 3) is being filled with early-stage chemistry work to free up capacity at Units 1 and 2. Management expects the regulator to take one to two years to clear it for finished products. - Peptides are a strategic bet. The company says it is the only one that starts from basic raw materials and builds its own peptide building blocks, protected amino acids, di- and tri-peptides and fragments. It is adding several 3,000-litre solid-phase peptide synthesis reactors.

Divi's Labs generics pipeline

About four drug master files (DMFs) have been filed in recent years. Validation quantities are with customers. One customer is discussing long-term exclusivity. For Brivaracetam and Ticagrelor, management expects commercial volumes in three to six months once customers finish qualification.

The growth driver in one line Divi's profit is growing almost three times faster than its sales because the mix is moving to custom synthesis, and the new capex is still to add its first commercial revenue.

How Divi's Labs valuation compares with peers

Company Price (₹) P/E Market cap (₹ crore) ROCE --------------- Divi's Laboratories 11,180 86.9 2,96,807 22.0% Laurus Labs 2,295 92.5 1,23,980 17.8% Sun Pharma 1,885 36.8 4,52,251 20.5% Dr Reddy's Labs 1,390 41.5 1,16,119 13.0% Cipla 1,415 36.8 1,14,316 15.5%

Source: screener.in peer table, 21 November 2026 (consolidated). Laurus Labs is the closest peer in API and CDMO work. Divi's is priced at a similar P/E to Laurus and at more than twice the P/E of Sun Pharma or Cipla.

The same peer table already shows Divi's September 2026 quarter: net profit ₹1,127 crore (up 63.6%) on sales of ₹3,676 crore (up 35.4%). This article covers the Q1 FY27 call only.

What Divi's Labs management said about the future

These are management's own forward-looking statements. They are not facts and not promises.

- Revenue: no formal FY27 revenue or profit guidance. Management said it will show double-digit revenue growth "no matter what" and "for sure" for the year. - Margins: judge on a yearly basis. Custom synthesis at 60% gave margins slightly higher than the previous quarter, but the mix can swing from quarter to quarter. - Capex: the three major projects are near completion and in validation. About ₹2,000 crore in total, about 70% capitalised. - Peptides: qualification of several fragments is expected to advance over the coming quarters. More 3,000-litre reactors are being added. Goal: the largest integrated peptide player. - Generics: about four DMFs filed. Commercial volumes of Brivaracetam and Ticagrelor are expected in three to six months after customer qualification. - Supply chain: three months of rolling raw material stock will continue while West Asia remains uncertain.

Divi's Labs risks

- Solvent costs and West Asia supply disruption. Management said solvent prices flatten for a few weeks and then rise again. - Commercial revenue from the new capex depends on customer and regulator approvals that the company does not control. - Custom synthesis revenue is lumpy. Q1 was strong, but management would not promise a 60:40 mix. - Valuation: P/E of 86.9 leaves little room for a miss. - Inventory of ₹4,413 crore and receivables of ₹3,056 crore tie up cash. The extra stock was bought at higher prices.

Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.

Sources

- https://www.bseindia.com/xml-data/corpfiling/AttachLive/624ad153-de0d-4ff3-90cc-dfe120771dcc.pdf (Divi's Laboratories Q1 FY27 earnings call transcript, filed 6 August 2026)